Altimmune Inc (NASDAQ:ALT) price on Tuesday, December 24, fall -2.71% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $7.55.
A look at the stock’s price movement, the close in the last trading session was $7.76, moving within a range at $7.5 and $7.8. The beta value (5-Year monthly) was 0.072. Turning to its 52-week performance, $14.84 and $5.28 were the 52-week high and 52-week low respectively. Overall, ALT moved -12.56% over the past month.
Altimmune Inc’s market cap currently stands at around $522.46 million, with investors looking forward to this quarter’s earnings report slated for in January.
The average forecast suggests down to a -100.00% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 3.57k, representing a -99.16% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that ALT is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend ALT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ALT’s current price about -13.00% and -4.82% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 41.86, while 7-day volatility ratio is 7.45% and 8.43% in the 30-day chart. Further, Altimmune Inc (ALT) has a beta value of 0.17, and an average true range (ATR) of 0.71. Analysts have given the company’s stock an average 52-week price target of $25, forecast between a low of $12 and high of $35. Looking at the price targets, the low is -58.94% off current price level while to achieve the yearly target high, price needs to move -363.58%. Nonetheless, investors will most likely welcome a -231.13% jump to $25 which is the analysts’ median price.
If we refocus on Altimmune Inc (NASDAQ:ALT), historical trading data shows that trading volumes averaged 3.1 over the past 10 days and 3.09 million over the past 3 months. The company’s latest data on shares outstanding shows there are 71.12 million shares.
The 0.83% of Altimmune Inc’s shares are in the hands of company insiders while institutional holders own 55.99% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 23.43 million on 2024-11-29, giving us a short ratio of 5.81. The data shows that as of 2024-11-29 short interest in Altimmune Inc (ALT) stood at 3304.0002 of shares outstanding, with shares short rising to 22.94 million registered in 2024-10-31. Current price change has pushed the stock -32.54% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ALT stock continues to rise going into the next quarter.
